CEO Anne Wojcicki on turning 23andMe into a ‘full-fledged biotech’

23andMe always had larger aims than at-home genetics testing. In this in-depth interview, Wojcicki explains the company’s foray into drug R&D.

Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks